In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...

Across social media and encrypted messaging apps, a new frontier of weight loss is unfolding in real time, with people sourcing and injecting an experimental drug that regulators have not yet approved ...

An experimental oral drug claims to do the work of medications like GLP-1s without losing muscle mass. The medication just went through phase 1 clinical trials. Doctors explain the new medication and ...

Feb 3 (Reuters) - Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight loss in patients without diabetes in a mid-stage trial. In ...

Both the new weight loss drugs and bariatric (weight loss) surgery improve body composition in patients with obesity by inducing a moderate loss of fat-free mass (including lean muscle) along with a ...

Some people don’t lose enough weight after bariatric surgery, but a new study shows that adding a daily shot of GLP-1 drug liraglutide can help patients shed extra pounds and may reduce the need for ...

Eli Lilly and Co (NYSE: LLY) on Thursday shared topline results from the Phase 3 TRIUMPH-4 trial evaluating the two highest investigational doses of retatrutide. Retatrutide is a GIP, GLP-1, and ...

“Weight-loss methods, whether with pharmacotherapy or surgery, have to be mindful to avoid inducing these complications,” ...

The blockbuster weight loss drug market is entering a new chapter of growth. Eli Lilly and Novo Nordisk are both focused on fighting for market share, ramping up supply, testing new uses for their ...

The battle of the bulge! With two strong contenders in the ring — surgery and medications — thousands of patients have had success shedding weight, but is there a clear champion? For many people like ...

Bariatric surgery is more cost-effective and offers better long-term outcomes than GLP-1 RAs for obesity and metabolic comorbidities. GLP-1 RAs face challenges like high costs, limited insurance ...